Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Tandem Diabetes Care (TNDM)
NASDAQ:TNDM
Tandem Diabetes Care (TNDM) Stock Price & Analysis
1,305 Followers
TNDM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$13.82 - $47.88
Previous Close$47.3
Volume1.12M
Average Volume (3M)1.91M
Market Cap
$3.06B
Enterprise Value$3.00B
Total Cash (Recent Filing)$467.91M
Total Debt (Recent Filing)$415.67M
Price to Earnings (P/E)-21.8
Beta1.61
Next Earnings
Aug 01, 2024EPS Estimate
-$0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.17
Shares Outstanding64,589,518
10 Day Avg. Volume1,408,381
30 Day Avg. Volume1,910,009
Standard Deviation0.17
R-Squared0.12
Alpha-0.00556
Financial Highlights & Ratios
Price to Book (P/B)9.66
Price to Sales (P/S)4.09
Price to Cash Flow (P/CF)-105.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.02
Enterprise Value/Gross Profit8.17
Enterprise Value/Ebitda-20.53
Forecast
1Y Price Target
$43.75Price Target Upside-7.51% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering13
Tandem Diabetes Care News
Bulls Say, Bears Say
Bulls Say
Financial Performance And GuidanceManagement's upward revision of 2024 global revenue guidance reflects confidence in TNDM's growth trajectory and suggests potential for future financial outperformance.
Market Share And Product AcceptanceTNDM has captured a significant portion of the U.S. insulin pump market with its advanced Control-IQ AID system, demonstrating strong market acceptance and potential for continued growth.
Product Pipeline And Market OpportunityTNDM's innovative product launches, including the highly anticipated Mobi, and the potential for expanded pharmacy access, present an attractive investment opportunity with favorable risk/reward dynamics.
Bears Say
Financial PerformanceTandem was caught between product cycles and hence delivered lackluster results with non-GAAP revenue down -4.0% and AEBITDA fell from $53.4M in 2022 to -$9.2M in 2023.
Market CompetitionChallenges such as declining MDT user base, improved competitor user retention, and increasing competition from MDI solutions may pressure the company in the upcoming years.
Product AdoptionTNDM's lack of broad pharmacy access is expected to limit Mobi's adoption in T2D patients.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
TNDM FAQ
What was Tandem Diabetes Care’s price range in the past 12 months?
Tandem Diabetes Care lowest stock price was $13.82 and its highest was $47.88 in the past 12 months.
What is Tandem Diabetes Care’s market cap?
Currently, no data Available
When is Tandem Diabetes Care’s upcoming earnings report date?
Tandem Diabetes Care’s upcoming earnings report date is Aug 01, 2024 which is in 75 days.
How were Tandem Diabetes Care’s earnings last quarter?
Tandem Diabetes Care released its earnings results on May 02, 2024. The company reported -$0.65 earnings per share for the quarter, beating the consensus estimate of -$0.761 by $0.111.
Is Tandem Diabetes Care overvalued?
According to Wall Street analysts Tandem Diabetes Care’s price is currently Overvalued.
Does Tandem Diabetes Care pay dividends?
Tandem Diabetes Care does not currently pay dividends.
What is Tandem Diabetes Care’s EPS estimate?
Tandem Diabetes Care’s EPS estimate is -$0.55.
How many shares outstanding does Tandem Diabetes Care have?
Tandem Diabetes Care has 64,589,516 shares outstanding.
What happened to Tandem Diabetes Care’s price movement after its last earnings report?
Tandem Diabetes Care reported an EPS of -$0.65 in its last earnings report, beating expectations of -$0.761. Following the earnings report the stock price went up 22.319%.
Which hedge fund is a major shareholder of Tandem Diabetes Care?
Among the largest hedge funds holding Tandem Diabetes Care’s share is Driehaus Capital Management LLC. It holds Tandem Diabetes Care’s shares valued at 47M.
---
Tandem Diabetes Care Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$43.75 (-7.51% Downside)
$43.75 (-7.51% Downside)
Blogger Sentiment
Bullish
TNDM Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 2.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
55.54%
12-Months-Change
Fundamentals
Return on Equity
-48.62%
Trailing 12-Months
Asset Growth
-1.37%
Trailing 12-Months
Company Description
Tandem Diabetes Care
Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.
---
TNDM Company Deck
---
TNDM Earnings Call
Q1 2024
0:00 / 0:00
---
TNDM Revenue Breakdown
74.21% U.S.
25.79% International
---
TNDM Stock 12 Month Forecast
Average Price Target
$43.75
▼(-7.51% Downside)
Technical Analysis
Best Analysts Covering TNDM
1 Year
1 Year Success Rate
21/26 ratings generated profit
1 Year Average Return
+136.83%
reiterated a buy rating 8 months ago
Copying Steven Lichtman's trades and holding each position for 1 Year would result in 80.77% of your transactions generating a profit, with an average return of +136.83% per trade.
---